OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M

OPKO HEALTH, INC.

Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.
Net loss $8.4M ($0.01/share) vs $148.4M ($0.19/share) in Q2 2025.
Diagnostics revenue $74.5M (down from $101.1M due to oncology asset sale to Labcorp); pharma product revenue $42.9M.
Cash and equivalents $314.4M; $105.3M of stock repurchased under $200M program.
FY 2026 total revenue guidance $560-585M; Q3 2026 revenue guidance $131-142M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.